Cytec acquires Nastech's rights for MASCT
Cytyc Corporation, from Boxborough, MA, and Nastech Pharmaceutical of Bothell, WA, US, have signed an agreement under which Cytyc will acquire exclusive world-wide patent rights to products that make use of Nastech's FDA-approved Mammary Aspirate Specimen Cytology Test (MASCT).
Cytyc Corporation, from Boxborough, MA, and Nastech Pharmaceutical of Bothell, WA, US, have signed an agreement under which Cytyc will acquire exclusive world-wide patent rights to products that make use of Nastech's FDA-approved Mammary Aspirate Specimen Cytology Test (MASCT).
The MASCT is a non-invasive, non-powered device that draws Nipple Aspirate Fluid (NAF) from the breast for cytological examination or molecular analysis.
'The agreement with Cytyc will enable us to participate in the upside potential of this important product for the early detection and treatment of breast cancer while allowing us to continue to focus on our core technology in tight junction modulation and nasal drug delivery programs,' stated Steven C.Quay, chairman, president, and ceo of Nastech.
'We believe this technology is very complementary to our FirstCyte Breast Test and our recently announced research initiatives,' said Daniel J. Levangie, president and ceo of Cytyc Health Corporation, a wholly owned subsidiary of Cytyc Corporation. 'In the future, we believe that the identification of specific molecular markers within NAF may aid in further stratifying patients at highest risk for developing breast cancer.'